InvestorsHub Logo
icon url

rosemountbomber

09/21/22 4:27 PM

#389216 RE: Tatsumaki #389213

Tatsumaki I have to agree with you. I don’t quite understand how this is not clear to people.
icon url

Monk44

09/21/22 4:42 PM

#389218 RE: Tatsumaki #389213

BP will handle "the market"
icon url

ziploc_1

09/21/22 5:45 PM

#389228 RE: Tatsumaki #389213

Its all about the serum EPA levels...An Rx for 4 gms/day of Vascepa yields a serum EPA level of 150...An Rx for 2 gms/day of MD-2119 yields a serum EPA level of 200....OR 50% MORE EPA in the MD-2119 Rx than in the Vascepa Rx!


Vascepa and MD-2119 are two different drugs...They are NOT bioequivalent... An Rx for 2gms/day of MD-2119 can NOT be substituted for by an Rx for 4 gms a day of Vascepa

Vascepa and MD-2119 are like apples and oranges...They are both fruits, but one is very different from the other..
icon url

ilovetech

09/21/22 5:56 PM

#389234 RE: Tatsumaki #389213

according to the patent, less source API required to manufacturer the self-emulsifying pill. Manufacturing efficiency is elevated to a new level that includes:

- Ethanol is not required
- Chances of errors and oxidation is minimal at worst.
- The formulation offers more stability minus the substrates seen in 2.0.
- Assuming the features above are accurate, 2.0 should be less expensive not more.

ILT